Background. Travelers to malarious areas are at risk of acquiring malaria; however, with chemoprophylaxis and prompt, effective therapy, serious complications of infection are generally preventable. In June 2002, we investigated a report of a cluster of malaria cases among US university staff and students who visited Ghana and were reportedly adherent to appropriate malaria chemoprophylaxis.
out the southeastern United States. With improved socioeconomic conditions, water management, vectorcontrol, and case management, malaria transmission was interrupted, leading to the eradication of malaria, which was officially certified in the 1970s [2, 3] . In the United States, malaria continues to be a reportable illness; of the ∼1500 cases diagnosed and reported annually, most are among persons returning from travel to countries where malaria is endemic [4] .
Among this population, malaria illness and serious complications are generally preventable through the use of chemoprophylactic drugs, personal protective measures (including use of insect repellent containing N,Ndiethyl-meta-toluamide [DEET] , insecticide-treated bednets, long-sleeved shirts, and long trousers) [5] , early detection of febrile illness, and prompt and effective therapy. The Centers for Disease Control and Prevention (CDC; Atlanta, GA) recommends the use of malaria chemoprophylaxis for travelers based on anti-malarial drug resistance patterns in the region of intended travel. For regions where Plasmodium falciparum is still susceptible, chloroquine is the chemoprophylaxis of choice. In regions where chloroquine-resistant P. falicparum is widespread, options include atovaquone-proguanil, doxycycline, or mefloquine. In some circumstances, primaquine may be an appropriate alternative agent [5] .
Some travelers, however, may still develop malaria despite having received appropriate pretravel malaria prophylaxis advice and despite adhering to chemoprophylaxis while abroad. This may be a result of inadequate protective blood levels of the drug (poor absorption or rapid metabolism of the chemoprophylactic agent) or parasite resistance to the drug. When chemoprophylaxis failure is suspected, it is first necessary to confirm that the diagnosis of malaria was correct. If confirmed, it is important to evaluate whether the infection was due to inadequate drug levels or to possible parasite drug resistance to guide future chemoprophylaxis recommendations for travelers.
Anecdotal reports of travelers who are reportedly adherent to recommended prophylaxis and who have had malaria diagnosed in countries where it is endemic are frequent. It is not possible for many of these reports to be investigated in a timely manner, which makes it difficult to draw conclusions about the circumstances of the infection. In addition, some travelers may receive misdiagnoses while abroad, leading them to attribute their symptoms erroneously to malaria.
In June 2002, the CDC received a report of a series of possible chemoprophylaxis failures among a group of students participating in a university exchange program in Ghana. A number of these students had reported receiving diagnoses of malaria while abroad and while apparently taking recommended malaria chemoprophylaxis. In an attempt to verify this, the CDC and the Georgia Division of Public Health (Atlanta) conducted an investigation to verify the reports of malaria infection, the use of appropriate antimalarials for chemoprophylaxis, and the likelihood of parasite resistance to these regimens.
METHODS

Population.
College students and staff who had traveled to Ghana for ∼1 month from mid-May through early June 2002 as part of a US university cultural exchange program were evaluated. The CDC and Georgia Division of Public Health worked with the health clinic and office of international education at the university to obtain a complete list of participating students and staff. This investigation was conducted in compliance with all applicable federal regulations governing the protection of human subjects research.
Questionnaires. We administered a questionnaire by telephone to students and staff upon their return to the United States from Ghana. We collected information on demographic characteristics, previous travel history and previous episodes of malaria, use of malaria chemoprophylaxis and personal protection measures during the trip, symptoms of illness, medical care sought and diagnoses made while in Ghana, and medical care sought upon return to the United States. Verbal consent to participate in the investigation was given by all persons interviewed.
Serological examination. We collected venous blood specimens from patients with a history of malaria diagnosed by blood smear in Ghana within 6 months after symptom onset. Serum specimens were tested at the CDC for the presence of malaria antibodies by the indirect fluorescent antibody (IFA) test with antigens of all 4 human Plasmodium species. Antibody titers of у1:64 are considered to be indicative of infection at some time (test sensitivity, 95%; test specificity, 99%) [6, 7] . Written consent was obtained for those persons submitting blood specimens for serological examination.
Statistical analysis. Categorical variables were analyzed using frequency distributions.
RESULTS
Thirty-three individuals (28 students and 5 staff members) participated in the exchange program to Ghana during May and June 2002. This exchange program is an annual activity coordinated by the university. Students and staff who participate in the program are primarily from the coordinating university, although those from other US universities may also participate.
Twenty-five (21 students and 4 staff members; 76%) of the 33 participants were interviewed and completed the questionnaire. Eight participants were not interviewed (1 refused, and 7 were unable to be contacted because of a disconnected phone or because they did not answer the phone or did not return a minimum of 3 successive phone messages). Sixteen participants were women, and 9 were men; the median age of interviewed participants was 26 years. Only 3 members of the group had traveled to regions where malaria is endemic in the past; 1 reported a prior history of malaria. Participants arrived in Accra, Ghana, on 12 May. The group spent 7 days in the capital before departing for other smaller towns and villages. All but 1 of the participants were prescribed a CDC-recommended drug for malaria chemoprophylaxis (atovaquone-proguanil for 15 persons, mefloquine for 6 persons, and doxycycline for 3 persons). All of those interviewed reported using insect repellent containing DEET on their skin to avoid mosquito bites during their travels. Only 2 participants reported sleeping under a bednet, a recommended adjunctive measure to prevent malaria infection in travelers. There were no reports of adverse reactions to chemoprophylaxis. Table 1 summarizes the demographic characteristics and selected results from the posttravel questionnaires.
While in Ghana, 20 of the 25 interviewed participants reported illness. The median time from the day of arrival in Ghana to the onset of symptoms was 12 days (range, 1-19 days). Overall, gastrointestinal symptoms were most commonly reported (diarrhea, 75% of persons; nausea and/or vomiting, 60%; and loss of appetite, 45%); other symptoms included chills (40% of persons), headache (40%), abdominal pain (40%), and fever (30%). Table 2 summarizes the symptoms experienced by ill participants while they were in Ghana. Among those with symptoms, 13 (65%) sought medical attention while in Ghana. Eleven of those who sought care had a laboratory test for malaria performed; 10 reported having had a blood smear performed, and 1 was unable to recall the type of test. The blood smears were performed by health care providers in 2 locations: Bolgatanga ( ) and Kumasi ( ). Six n p 4 n p 6 persons undergoing blood smear examination reported being told they had a test result positive for malaria and were subsequently treated with antimalarials. Among these persons with a positive test result, the median time to onset of illness was 14 days (range, 8-19 days), consistent with the minimum incubation period for P. falciparum malaria of 7 days. Antimalarials reported by participants included chloroquine (both oral and injectable preparations) and artemisinin derivatives. Table 3 summarizes the participants' adherence to their prescribed chemoprophylaxis. For the purpose of this investigation, complete adherence was defined as taking all doses of the prescribed prophylactic drug before, during, and after exposure, in accordance with the recommended schedule. Among the participants interviewed, 14 (56%) reported complete adherence to the prescribed chemoprophylaxis regimen; 12 (80%) of 15, 2 (34%) of 6, and 0 (0%) of 3 participants who received atovaquone-proguanil, mefloquine, and doxycycline, respectively, were adherent. Reasons for incomplete adherence were not evaluated with the questionnaire. Of note, 3 of the 6 persons who were told they had a positive blood smear result in Ghana were reportedly adherent to chemoprophylaxis (all taking atovaquone-proguanil), raising concerns regarding the possibility of chemoprophylaxis failure because of drug resistance.
No blood smears prepared in Ghana (upon which the original diagnoses were made) were available for review. Serological examination was used to evaluate the reported history of malaria. Participants with a reported blood smear-confirmed diagnosis of malaria in Ghana were asked to provide blood samples for serological testing. Five of the 6 patients for whom malaria was diagnosed in Ghana provided specimens for testing; 1 participant refused. All 5 specimens tested negative for all 4 species of malaria. These results suggest that these participants had never been exposed to malaria and thus most likely received an incorrect diagnosis of malaria in Ghana.
DISCUSSION
With a population increasingly traveling abroad (there were ∼23 million travelers from the United States in 2002 [8] ) and many of these travelers visiting regions where malaria is endemic, malaria among returning travelers is likely to become increasingly frequent. In addition, despite CDC malaria chemoprophylaxis recommendations, serious malaria-associated morbidity and mortality continue to occur among travelers. In 2001, there were 11 reported deaths attributable to malaria; all involved US civilians who had recently traveled abroad to regions where malaria is endemic [4] . An earlier review of deaths attributable to malaria in the United States identified certain risk factors for fatal malaria, including failure to take the recom- mended antimalarial chemoprophylaxis, delay in seeking medical care, and misdiagnosis [9] . Among US civilians with cases reported to the CDC in 2001, ∼78% were not taking any chemoprophylaxis or were taking a nonrecommended drug for prophylaxis [4] . The CDC is responsible for providing malaria chemoprophylaxis recommendations for US travelers; thus, reports of travelers acquiring malaria despite taking recommended antimalarials are of particular concern and warrant further investigation. The investigation described in this paper was initiated in response to such a report. In this instance, the report was particularly alarming, because the suspected cases were among persons with reported appropriate use of atovaquoneproguanil, a relatively new chemoprophylactic drug with good efficacy [10, 11] . No previous reports suggesting such chemoprophylaxis failure have been confirmed, although there have been well-documented treatment failures [12, 13] . The ensuing investigation not only demonstrated the importance of confirmation of the diagnosis, but it also highlighted some additional potential risks associated with misdiagnosis of malaria while abroad.
When chemoprophylaxis failure is suspected, it is first necessary to confirm the malaria infection. Serological examination can be a useful tool for identifying individuals with recent malaria infection when patent parasitemia, as detected by blood film examination or PCR, is no longer detectable. The IFA test is sensitive and specific (sensitivity, 95%; specificity, 99%), and infection is inferred when an individual has elevated levels of antibodies to any one or more of the 4 species of malaria infecting humans [6] . For an individual who has experienced symptoms consistent with malaria and who has traveled recently to a region where malaria is endemic, a negative test result is a reliable way to exclude infection with Plasmodium species. It is possible that serological test results may be negative if a patient did not mount an adequate immune response because of early receipt of treatment or to immunodeficiency syndromes. The sensitivity of serological testing does decrease with time after chemotherapeutic cure [7] . However, given that all 5 participants who received a diagnosis of malaria were tested for the presence of malarial antibodies within 6 months after symptom onset and experienced symptoms for a number of days before being diagnosed and treated, we believe that the results of serologic tests confirm that they did not acquire malaria while in Ghana.
Because the blood smears from Ghana were unavailable for review, serological testing was vital to establish whether the initial diagnoses of malaria were correct among the participants who had reported a diagnosis of malaria. On the basis of the negative serological test results, concern regarding chemoprophylaxis failure seemed unfounded.
Misdiagnosis of malaria may lead to a number of inappropriate actions or behaviors, putting the traveler at additional and unnecessary risk. First, misdiagnosis may lead to prescription and administration of inappropriate treatments. Such inappropriate treatments have been reported elsewhere to have had fatal consequences [14] . There were no such adverse outcomes among the group of persons who traveled to Ghana. However, this group did report the administration of chloroquine (including injectable preparations) for the treatment of malaria. This antimalarial is no longer recommended by the CDC, given the high levels of chloroquine resistance reported in West Africa [5] . Not only are patients treated with chloroquine likely to have treatment failure and to experience serious complications of the disease, but injectable preparations of any type potentially expose the patient to a number of blood-borne diseases (such as HIV infection and hepatitis) through the use of inadequately sterilized equipment.
Misdiagnosis of malaria may also lead travelers to change or cease chemoprophylaxis on the basis of the belief that the chemoprophylaxis did not offer the expected protection. This practice puts the traveler at increased risk of truly acquiring malaria for the remainder of their travels and propagates rumors of chemoprophylaxis failure. Anecdotal reports of this phenomenon were evident during administration of the questionnaire among the participants of the Ghana trip. This extended beyond the immediate group with a diagnosis of malaria and impacted behaviors of the entire group. This phenomenon is highlighted by the incomplete adherence to treatment reported in the questionnaire: almost one-half the group was nonadherent to the prescribed antimalarial chemoprophylaxis.
The use of chemoprophylaxis and other strategies in the prevention of serious and potentially fatal malaria outcomes is critical. The results of this investigation also suggest that there is a need to improve prevention behaviors: 44% were not adherent to chemoprophylaxis, 35% did not seek medical attention for symptoms consistent with malaria, few slept under bed nets; insect repellent was used daily by most participants. Incomplete adherence was observed among all chemoprophylactic regimens, including both daily (atovaquone-proguanil and doxycycline) and weekly (mefloquine) regimens. Because numbers were small and reasons for incomplete adherence were not evaluated, it is difficult to draw conclusions regarding whether one chemoprophylactic regimen was superior to another among this group. The absence of reports of adverse reactions suggests this was unlikely to be a significant reason contributing to incomplete adherence.
Alternative diagnostic methods exist. Rapid malaria antigen tests, also known as "rapid diagnostic tests" (RDTs), are commercially available and are capable of identifying malaria parasitemia. These tests are relatively simple to perform, and the results are relatively simple to interpret, and they may be appropriate for diagnosis of malaria in areas where microscopy is unavailable or unfeasible [15] . However, several factors limit the ability to recommend the use of RDTs by US travelers. First, reports of RDT use by travelers for self-diagnosis is limited. Second, there are no RDTs currently approved for use in the United States. Third, there are data suggesting that these tests do not have adequate sensitivity at the low parasite densities that can cause disease in nonimmune travelers to avoid potentially false-negative results. Fourth, there are concerns regarding the ability of ill travelers to perform the test and to manage their illness appropriately [16] . Therefore, use of RDTs by US travelers to areas of endemicity is not recommended at this time.
In summary, there was no evidence to suggest chemoprophylaxis failure with atovaquone-proguanil or any other chemoprophylactic drug used among this group. As a consequence of misdiagnosis and perceived failure of chemoprophylaxis, several participants received unnecessary treatment, and a number of participants modified their adherence and even ceased taking their chemoprophylaxis altogether. We believe that this investigation highlights the need to provide adequate pretravel information and for travelers to understand the importance of adherence to chemoprophylaxis. If any illness occurs, prompt medical attention should be sought. Of note, although fever and chills are classic symptoms of malaria, gastrointestinal and respiratory symptoms may also be attributable to malaria. Investigation of any illness should be encouraged and should include rapid, accurate diagnosis, followed by safe, effective treatment. It would be preferable for programs, such as the one conducted by this university, that send groups abroad to identify reputable local health care facilities where accurate diagnosis and effective treatment can be sought. Another suggestion is to inform travelers to retain any blood smears prepared overseas for review upon return to the United States, which would be helpful in determining whether malaria was the cause of the illness. It is also essential for public health agencies to critically evaluate reports of chemoprophylaxis failure and to determine whether these could potentially represent drug resistance. CDC personnel and laboratory resources are available to assist in such investigations.
